ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (RMD) is back in focus after reporting higher sales and net income for ...

Indiana officials have committed to giving the company behind an upcoming Greenwood distribution center up to $1.75 million in tax credits.

Sydney: Sleep-breathing device maker ResMed plans to take global a doctor ‍education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, ⁠calling ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...

SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed (RMD.N), opens new tab plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style ...

ResMed NASDAQ:RMD Chairman and CEO Michael J. Farrell sold 4,991 shares of company stock on February 9, 2026, for approximately $1.36 million. The sales were executed at a weighted average price of ...

Now could be the time to buy ResMed Inc (ASX: RMD) shares. That's the view of analysts at Morgans, who have turned positive on the sleep disorder-focused medical device company following its ...

ResMed Earnings Call Highlights Strong Growth, Expanding Margins and Shareholder Returns ResMed’s latest earnings call struck a notably upbeat tone, underscoring broad-based strength across revenue, ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...